# Project Handover Document

## Pharmacovigilance Intelligence System

## 1. Purpose

This document provides the information required for another developer, researcher, reviewer, or team member to understand, run, test, maintain, and continue the Pharmacovigilance Intelligence System.

The project is currently a research and development prototype for retrieving and organizing drug safety evidence.

---

## 2. Project Status

**Overall Status:** Prototype implementation completed

**Automated Testing:** Completed

**Recorded Test Result:** `10 passed`

**Documentation:** Completed for the current implementation

**Production Deployment:** Not claimed

The system should be treated as a development/research prototype rather than a production clinical pharmacovigilance platform.

---

## 3. Project Purpose

The system demonstrates an evidence pipeline for pharmacovigilance data.

Its main workflow is:

**Drug Input → OpenFDA API → Data Processing → Evidence Normalization → Validation → Storage → Retrieval / Review**

The system focuses on structured handling of safety evidence while preserving source and provenance information.

---

## 4. Main Project Components

| Component | Location | Purpose |
|---|---|---|
| Main application | `app.py` | Coordinates the application workflow |
| OpenFDA connector | `src/openfda_connector.py` | Retrieves drug safety information |
| Evidence schema | `src/evidence_schema.py` | Defines the evidence structure |
| Evidence normalizer | `src/normalize_evidence.py` | Normalizes retrieved evidence |
| Evidence store | `src/evidence_store.py` | Stores evidence and handles duplicates |
| Automated tests | `tests/test_phase4.py` | Tests implemented system behavior |

---

## 5. Project Structure

The current project is organized approximately as follows:

Pharmacovigilance_Project/

    src/
        __init__.py
        evidence_schema.py
        evidence_store.py
        normalize_evidence.py
        openfda_connector.py

    tests/
        test_phase4.py

    docs/
        data_dictionary.md
        dataset_evaluation.md
        dataset_registry.md
        learning_notes.md
        runtime_proof.md

    evidence_packet/
        screenshots/
        code_packet/
        runtime_logs/
        api_samples/
        deployment_proof/

    app.py
    openfda_test.py
    test_normalization.py
    evidence_output.json

    README.md
    ARCHITECTURE.md
    INTEGRATION.md
    HANDOVER.md
    CHANGELOG.md
    REVIEW_PACKET.md

---

## 6. Development Environment

The project was developed and tested using:

- Python
- Visual Studio Code
- OpenFDA API
- pytest
- `requests`

Internet access is required when the application needs to communicate with the external OpenFDA API.

---

## 7. Installation

Open the project folder in Visual Studio Code.

Open the integrated terminal and install the required Python packages:

`python -m pip install requests pytest`

If the environment already has the required packages installed, this step may not be necessary.

---

## 8. Running the Application

From the project root, run:

`python app.py`

The application starts the implemented drug safety workflow.

The user provides a drug name and the application communicates with the configured OpenFDA source.

---

## 9. Running the Automated Tests

From the project root, run:

`python -m pytest tests/test_phase4.py -v`

The recorded successful result was:

`10 passed`

This is the final documented Phase 4 test result from the completed development workflow.

---

## 10. Important Files for Maintenance

### `app.py`

This is the main application entry point.

Changes to the overall application workflow should begin here.

---

### `src/openfda_connector.py`

This module handles communication with the OpenFDA API.

If the API endpoint, request structure, or API-specific behavior changes, this module should be reviewed first.

---

### `src/evidence_schema.py`

This module defines the normalized evidence structure.

Changes to evidence fields should be reflected in:

- The data dictionary
- Normalization logic
- Storage logic
- Automated tests
- Documentation

---

### `src/normalize_evidence.py`

This module converts retrieved source information into the internal evidence representation.

Changes to source-field mapping should be reviewed here.

---

### `src/evidence_store.py`

This module handles evidence persistence and duplicate-related behavior.

Changes to storage format or duplicate logic should be tested carefully before use.

---

### `tests/test_phase4.py`

This is the primary documented Phase 4 automated test suite.

Any major changes to application behavior should be accompanied by corresponding test updates.

---

## 11. Documentation Files

### `README.md`

Provides the main project overview, setup instructions, usage information, architecture summary, limitations, and project status.

### `ARCHITECTURE.md`

Describes the internal architecture and component responsibilities.

### `INTEGRATION.md`

Describes how the major project components connect and interact.

### `HANDOVER.md`

Provides this maintenance and continuation guide.

### `CHANGELOG.md`

Records project changes between versions or development stages.

### `REVIEW_PACKET.md`

Provides a consolidated review-oriented project summary and evidence references.

---

## 12. Documentation Directory

The `docs/` directory contains detailed supporting documentation.

### `docs/dataset_registry.md`

Documents the datasets and evidence sources used by the project.

### `docs/dataset_evaluation.md`

Documents the evaluation and limitations of the available data.

### `docs/data_dictionary.md`

Defines the normalized evidence fields.

### `docs/learning_notes.md`

Records technical learning and implementation experience.

### `docs/runtime_proof.md`

Documents runtime verification and testing evidence.

---

## 13. Evidence Packet

The `evidence_packet/` directory is intended to organize supporting project evidence.

Its main directories are:

- `screenshots/`
- `code_packet/`
- `runtime_logs/`
- `api_samples/`
- `deployment_proof/`

These directories should contain supporting evidence only when the corresponding artifacts have actually been generated or captured.

Do not create false runtime logs, screenshots, API responses, or deployment evidence.

---

## 14. Data Source

The primary external source currently used by the project is:

**OpenFDA / FAERS-related drug-event data**

The system retrieves publicly available safety information through the OpenFDA API.

The quality and completeness of retrieved evidence depend partly on the underlying source data.

---

## 15. Evidence Handling

The project follows the general evidence lifecycle:

**Source → Retrieval → Processing → Normalization → Validation → Storage**

The system attempts to preserve provenance so that normalized evidence can remain connected to its source.

Missing information should not be invented.

---

## 16. Duplicate Handling

The evidence store includes duplicate handling.

The intended behavior is:

**New evidence → Check existing evidence → Store only if not already present**

This prevents unnecessary repeated storage of the same evidence.

If duplicate behavior is modified, the automated tests should be executed again.

---

## 17. Error Handling

Important error situations include:

- API request failures
- No-result responses
- Missing source fields
- Invalid evidence structures
- Storage failures

Future maintainers should avoid silently ignoring errors.

Errors should be handled in a way that makes debugging and evidence traceability possible.

---

## 18. Testing Expectations

Before considering a significant change complete:

1. Save the modified code.
2. Run the relevant automated tests.
3. Confirm that tests pass.
4. Test the affected application workflow where appropriate.
5. Update documentation if behavior or architecture changed.

The baseline recorded result is:

`10 passed`

Future changes may require additional tests.

---

## 19. Recommended Maintenance Workflow

For future development:

### Step 1

Create a backup or version-control checkpoint.

### Step 2

Identify the module affected by the change.

### Step 3

Modify only the required component.

### Step 4

Run the relevant tests.

### Step 5

Run the application if the change affects runtime behavior.

### Step 6

Review evidence output.

### Step 7

Update documentation.

### Step 8

Record the change in `CHANGELOG.md`.

### Step 9

Re-run the full available test suite before final handover.

---

## 20. Changing the Evidence Schema

If a new evidence field is added:

1. Update `src/evidence_schema.py`.
2. Update `src/normalize_evidence.py`.
3. Update storage handling if required.
4. Update automated tests.
5. Update `docs/data_dictionary.md`.
6. Update `README.md` if the change affects user-facing behavior.
7. Update `ARCHITECTURE.md` or `INTEGRATION.md` if the architecture changes.

Schema changes should be treated carefully because they can affect multiple components.

---

## 21. Changing the API Integration

If the OpenFDA integration changes:

1. Review `src/openfda_connector.py`.
2. Verify the API endpoint and request structure.
3. Check response parsing.
4. Check error handling.
5. Test with a valid drug query.
6. Test a no-result query.
7. Run the automated tests.
8. Update integration documentation.

Do not assume that an external API will always return the same response structure.

---

## 22. Production Considerations

The current project is not presented as a production clinical system.

Before production deployment, additional work would be required in areas such as:

- Security
- Authentication
- Authorization
- Database architecture
- API monitoring
- Logging
- Audit trails
- Backup and recovery
- Rate-limit management
- Data-quality monitoring
- Automated deployment
- Infrastructure monitoring
- Regulatory and compliance review
- Pharmacovigilance expert validation

---

## 23. Pharmacovigilance Safety Boundary

The system retrieves and organizes reported safety evidence.

It does not independently establish clinical causality.

A reported adverse event should therefore not automatically be interpreted as:

**Confirmed drug-related adverse effect**

Instead, it should be treated as:

**Safety evidence requiring appropriate interpretation and assessment**

Clinical and regulatory decisions require qualified expert review.

---

## 24. Troubleshooting

### Problem: `ModuleNotFoundError`

Make sure the terminal is opened at the project root.

Run the tests using:

`python -m pytest tests/test_phase4.py -v`

rather than executing the test file from an unrelated directory.

---

### Problem: `requests` is not installed

Run:

`python -m pip install requests`

---

### Problem: `pytest` is not installed

Run:

`python -m pip install pytest`

---

### Problem: API request fails

Check:

- Internet connection
- OpenFDA availability
- API request parameters
- Error message returned by the application

Do not treat an API failure as evidence of no adverse events.

---

### Problem: No safety records found

Check the drug name and source response.

A no-result response does not mean that the drug is safe.

It only means that the current query did not return matching records from the source.

---

## 25. Handover Checklist

Before handing the project to another person, verify:

- [ ] Project opens successfully in VS Code.
- [ ] Required Python packages are installed.
- [ ] `app.py` can be executed.
- [ ] OpenFDA integration can be tested.
- [ ] Evidence normalization works.
- [ ] Evidence storage works.
- [ ] Duplicate handling works.
- [ ] Automated tests run successfully.
- [ ] Documentation is present.
- [ ] Runtime proof is updated.
- [ ] No unsupported runtime evidence has been added.
- [ ] Known limitations are documented.
- [ ] Changes are recorded in `CHANGELOG.md`.

---

## 26. Current Known Baseline

The current documented baseline includes:

**Primary source:** OpenFDA / FAERS

**Evidence representation:** Normalized pharmacovigilance evidence

**Storage:** Prototype JSON-based evidence storage

**Testing framework:** pytest

**Recorded Phase 4 test result:** `10 passed`

**Production status:** Prototype / research implementation

---

## 27. Future Development

Future maintainers may extend the system with:

- Additional safety-data sources
- Multi-source evidence integration
- More advanced normalization
- Improved identifier mapping
- Larger-scale storage
- Evidence search and indexing
- Signal detection
- Evidence ranking
- Natural-language evidence summaries
- Dashboards
- Monitoring
- Production deployment

Any future feature should be implemented, tested, and documented before being represented as completed functionality.

---

## 28. Final Handover Status

**Project implementation:** Completed prototype

**Phase 4 testing:** Completed

**Recorded result:** `10 passed`

**Documentation:** Completed for current implementation

**Production deployment:** Not claimed

The project is ready for review, controlled continuation, and future development based on the documented architecture and limitations.

---

## 29. Conclusion

The Pharmacovigilance Intelligence System provides a structured foundation for retrieving, processing, normalizing, validating, storing, and reviewing drug safety evidence.

This handover document provides the information required for another developer or researcher to continue the project without relying on undocumented assumptions.

Future development should preserve the project's core principles of:

- Evidence traceability
- Provenance preservation
- Structured normalization
- Explicit error handling
- Duplicate control
- Automated testing
- Responsible pharmacovigilance interpretation